Inicio>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Amoxicillin-d4

Amoxicillin-d4 (Synonyms: Amoxycillin D4)

Catalog No.GC40232

La amoxicilina D4 (Amoxicilina D4) es una amoxicilina marcada con deuterio.

Products are for research use only. Not for human use. We do not sell to patients.

Amoxicillin-d4 Chemical Structure

Cas No.: 2673270-36-3

Tamaño Precio Disponibilidad Cantidad
500μg
197,00 $
Disponible
1mg
375,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Amoxicillin-d4 is intended for use as an internal standard for the quantification of amoxicillin by GC- or LC-MS. Amoxicillin is an orally bioavailable, semisynthetic β-lactam antibiotic. It inhibits the growth of 30 isolates of P. mirabilis and 89% of 30 E. coli strains when used at concentrations greater than or equal to 5 and 10 µg/ml, respectively, but resistance develops in strains of Klebsiella, Enterobacter, and indole-positive Proteus species. Amoxicillin is susceptible to bacterial β-lactamases but is active against β-lactamase-producing bacteria when used in combination with β-lactamase antibiotics such as clavulanic acid with MIC values of greater than 4,096 and 16 µg/ml without or with clavulanic acid, respectively, against 46 clinical isolates of β-lactamase-producing E. coli. Formulations containing amoxicillin have been used in the treatment of a variety of bacterial infections.

Reseñas

Review for Amoxicillin-d4

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Amoxicillin-d4

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.